Browsing Tag
KRAS G12D
2 posts
Incyte’s dual-target antibody and KRAS G12D drug show early promise in hard-to-treat colorectal and pancreatic cancers
Find out how Incyte’s Phase 1 cancer data could transform treatment for colorectal and pancreatic patients—read what’s driving investor optimism today!
Revolution Medicines’ Zoldonrasib demonstrates early antitumor potential in kras g12d mutant lung cancer at AACR 2025
Find out how Revolution Medicines’ new data on zoldonrasib could reshape KRAS G12D mutant lung cancer treatment strategies.